rofecoxib (Vioxx) Report issue

Small molecule Withdrawn Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Rofecoxib is a nonsteroidal anti-inflammatory drug which selectively inhibits COX-2 and subsequent prostaglandin synthesis. The drug was developed by Merk and approved by FDA in 1999 for relief of signs and symptoms of arthritis, acute pain in adults, and painful menstrual cycles under the name Vioxx. Later on Merck voluntarily withdrawn Vioxx from the market due to safety concerns (high risk of heart attack and stroke).   NCATS

Chemistry

  • SMILES: CC(C)(N)CNC(=O)C[C@@H]1CC[C@@]2(CC1)OO[C@]3(O2)C4CC5CC(CC3C5)C4
  • InChIKey: VXYZBLXGCYNIHP-CAGINOIPSA-N
  • Mol. Mass: 392.54
  • ALogP: 3.25
  • ChEMBL Molecules:
    oz277  
    rofecoxib  
    arterolane  
More Chemistry

Pharmacology

Alternative names

4-(4-methylsulfonylphenyl)-3-phenyl-5h-furan-2-one | cahill may roberts brand of rofecoxib | ceeoxx | merck brand of rofecoxib | merck frosst brand of rofecoxib | merck sharp & dhome brand of rofecoxib | mk 0966 | mk-0966 | mk-1966 | mk 966 | mk-966 | msd brand of rofecoxib | refecoxib | rofecoxib | vioxx | vioxx dolor

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Osteoarthritis (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Acute Pain (Phase 4)

Adenomatous Polyposis Coli (Phase 4)

Alzheimer Disease (Phase 2/Phase 3)

Analgesics (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Arthropathy, Neurogenic (Phase 3)

Barrett Esophagus (Phase 4)

Brain Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2/Phase 3)

Colorectal Neoplasms (Phase 3)

Dysmenorrhea ()

Glioma (Phase 1)

Intestinal Polyposis (Phase 2/Phase 3)

Joint Diseases (Phase 2)

Migraine Disorders ()

Neoplasms (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain (Phase 4)

Pain, Postoperative (Phase 3)

Prostatic Neoplasms (Phase 3)

Stomach Neoplasms (Phase 3)

Tooth Extraction (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue